Literature DB >> 10471583

In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

J C de Azavedo1, L Trpeski, S Pong-Porter, S Matsumura, D E Low.   

Abstract

Among 418 blood culture isolates of viridans group streptococci obtained between 1995 and 1997, the in vitro rates of nonsusceptibility to penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 28, 29, 24, and 14%, respectively. The most prevalent group (125 strains) was Streptococcus mitis, followed by Streptococcus sanguis (56 strains). For 236 (56%) strains resistant to one or more antibiotics, the ciprofloxacin MIC at which 90% of the isolates were inhibited (MIC(90)) was 4 microg/ml, whereas the MIC(90)s of trovafloxacin, grepafloxacin, and gatifloxacin were 0.25 microg/ml.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10471583      PMCID： PMC89465     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Detection of decreased penicillin susceptibility in viridans group streptococci.

Authors:  S Pottumarthy; A J Morris
Journal:  Pathology       Date:  1998-05       Impact factor: 5.306

Review 2.  Erythromycin resistance by ribosome modification.

Authors:  B Weisblum
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

3.  Antimicrobial susceptibilities of species of viridans streptococci.

Authors:  A M Bourgault; W R Wilson; J A Washington
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

4.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

5.  Streptococcus mitis with unusually high level resistance to beta-lactam antibiotics.

Authors:  A König; R R Reinert; R Hakenbeck
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

6.  Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

Authors:  I González; M Georgiou; F Alcaide; D Balas; J Liñares; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 7.  Bacteremia due to viridans streptococci in neutropenic patients: a review.

Authors:  P Y Bochud; T Calandra; P Francioli
Journal:  Am J Med       Date:  1994-09       Impact factor: 4.965

8.  Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae.

Authors:  C G Dowson; T J Coffey; C Kell; R A Whiley
Journal:  Mol Microbiol       Date:  1993-08       Impact factor: 3.501

9.  Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci.

Authors:  R B Roberts; A G Krieger; N L Schiller; K C Gross
Journal:  Rev Infect Dis       Date:  1979 Nov-Dec

10.  Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

Authors:  L J Piddock; M Johnson; V Ricci; S L Hill
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
View more
  15 in total

1.  Potencies of newer fluoroquinolones against Viridans group Streptococciisolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): beyond Canada!

Authors:  R N Jones; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Antimicrobial susceptibilities and clinical sources of Facklamia species.

Authors:  L LaClaire; R Facklam
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

3.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002.

Authors:  Rajesh M Prabhu; Kerryl E Piper; Larry M Baddour; James M Steckelberg; Walter R Wilson; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  DNA relatedness, phenotypic characteristics, and antimicrobial susceptibilities of Globicatella sanguinis strains.

Authors:  P L Shewmaker; A G Steigerwalt; L Shealey; R Weyant; R R Facklam
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

8.  Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae.

Authors:  Paula Cerdá Zolezzi; Leticia Millán Laplana; Carmen Rubio Calvo; Pilar Goñi Cepero; Melisa Canales Erazo; Rafael Gómez-Lus
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

10.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.